



Pressure BioSciences, Inc.

Ticker: P BIO (OTCQB)

Corporate Profile

as of March 28, 2017

Pressure BioSciences, Inc. (OTCQB: P BIO) is a medical research products and technology company. Pressure BioSciences, Inc. (PBI), based in South Easton, Massachusetts, serves academic and government laboratories, as well as biotechnology, pharmaceutical, and other life sciences companies. PBI develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. PBI has installed approximately 300 sample preparation systems in approximately 160 sites worldwide.

PBI has developed and patented a cutting-edge technology platform that can exquisitely control sample preparation processes including the wide range of activities that precede many forms of scientific analysis. PBI's products harness the unique properties of thermodynamics for life science research laboratories. Sample preparation processes play a major role in biological research. With an estimated 500,000 scientists in over 80,000 research laboratories worldwide, PBI's products could offer solutions for many scientists who are seeking ways to enhance their processes. The PBI technology platform is based on constant (i.e., static) and alternating (i.e., Pressure Cycling Technology, or PCT) hydrostatic pressure; if used properly, pressure can help control the actions of molecules in biological samples, which can then have significant positive effects on scientific research studies. The Company offers products such as Barocycler Instruments, Shredder System and Consumables (PULSE and Micro Tubes). PBI holds 15 US patents covering multiple applications of PCT that offer significant advantages over competitive methods used to prepare samples for research evaluation.

PBI's development and sales efforts are in the biomarker discovery, drug discovery/design, and forensics areas. Potential customers could be expanded to areas such as: bio-therapeutics characterization, soil & plant biology, vaccine development, counter-bioterror applications and DNA studies. With these potential target areas, the growth potential for PBI is vast.

For Fiscal 2016, PBI reported an increase of annual product and service revenue of \$384,758 dollars, a 27% growth over the prior year. The Company reported an increase of annual consumables revenue of \$53,465 or 37% growth from the prior year. However, grant revenue declined by \$195,962. Despite this decline, total revenue for the fiscal year ended December 31, 2016 was \$1,976,487 compared to \$1,797,691 for the same period in 2015, a 10% increase.

One of the major improvements PBI has incorporated is in the area of its marketing its products. PBI has significantly expanded the Company's focus and capabilities in marketing and sales, which will significantly push the Firm forward for the remainder of 2017 and beyond. The Company has contracted with EKG Sales Associates, a life sciences lead generation service that has spent over 20 years developing their contact database with over 50,000 scientists and individuals from the life sciences field. With a focus on laboratory equipment and associated consumables, the new phase of marketing with EKG could be a significant jumpstart for the Company. In addition, PBI has recently hired two domestic sales executives to spearhead its growth and marketing initiatives. The Company plans to expand its staff to four additional field sales directors. PBI continues its two-year co-marketing agreement in 2017 with its large strategic partner named SCIEX, a global leader in life sciences analytical technologies and a wholly-owned subsidiary of the Danaher Corporation (NYSE: DHR). PBI also has developed relationships with distributors to market its products in Europe, Asia and the Pacific Rim.

In 2016 PBI produced five machines which were chosen to go to the cancer research project Cancer Moonshot, a project formerly led by Vice President Joe Biden, which aims to make more therapies available to more patients, while also improving the ability to prevent cancer to aid in and its early detection. Cancer Moonshot is \$1 Billion dollar initiative, which started with \$195 million in new cancer activities at the National Institutes of Health (NIH) in 2016. Since then, PBI launched the new Barocycler 2320EXTREME - the first major update of its flagship PCT-based sample preparation instrument in years. This release followed years of extensive user feedback. The compact, bench top instrument offers many features and benefits not found in its predecessor, including data logging options, user-level security, computer-operated control with touch screen programming, and the ability to customize multiple pressure cycling parameters. These new features and benefits should greatly expand the universe of potential users worldwide. PBI also has recently announced that it secured CE Marking for the Barocycler 2320EXTREME, which will enable the sales of its Barocycler instrument throughout 31 European countries.

The Company continues to meet or exceed its goals, and continues to give guidance that it anticipates an up-listing to a major exchange within the next few months, after it completes a planned secondary offering. On December 22, 2016, the Company filed with the SEC an S-1 Registration Statement to register 17.25 Million common shares plus warrants for the planned public secondary offering, which when completed will materially improve the Company's balance sheet. We believe P BIO shares are significantly undervalued given its core technologies, the size of its market, its management team and its history of success.

Table with 4 main sections: Income Statement, Balance Sheet, Cash Flow Statement, and a summary table. Columns include FY 2014, FY 2015, and FY 2016.



Sector: Healthcare
Industry: Medical Devices & Technology
Website: www.pressurebiosciences.com

Key Statistics

Table of key statistics including Price, 52 Week High/Low, Avg. Vol, Beta, Market Cap, Price/Sales, Insider Ownership, Shares Outstanding, Float, and EPS.

Source: Google / Yahoo Finance

Recent 2017 / 2016 Highlights

- March 23, 2017, PBI announced a significant expansion effort on marketing and sales capabilities.
February 9, 2017, PBI announced CE Marking for their next-generation Barocycler 2320EXTREME.
December 16, 2016, PBI announced the new Barocycler, has been selected and labeled as an essential technology for use in the Cancer Moonshot Initiative.
November 14, 2016, PBI announced it closed of \$610,000 in a private placement.
July 28, 2016, PBI announced an expanded co-marketing agreement with SCIEX to improve protein quantification in complex samples.

Corporate Contact Information

Pressure BioSciences, Inc.
Richard T. Schumacher, CEO
14 Norfolk Ave. South Easton MA, 02375
Phone: 508-230-1828
www.pressurebiosciences.com

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof.